ReviewInternational urogynecology journal2026
Efficacy of Platelet-Rich Plasma in Interstitial Cystitis/Bladder Pain Syndrome: A Systematic Review and Meta-Analysis.
Review in International urogynecology journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introduction and hypothesisInterstitial cystitis/bladder pain syndrome (IC/BPS) has been recognized as a chronic, debilitating disorder characterized by pelvic pain and urinary dysfunction, for which current therapies have offered limited long-term effectiveness. Recently, platelet-rich plasma (PRP), a biologic therapy rich in growth factors, has been investigated as a regenerative treatment option. MATERIALS AND
methodsThis systematic review and meta-analysis followed Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. This review was prospectively registered in the International Prospective Register of Systematic Reviews (CRD420251084131). Eight studies evaluating intravesical PRP for IC/BPS were included. Data were extracted from PubMed, Web of Science, CINAHL, and Cochrane Central Register of Controlled Trials. Risk of bias was evaluated using the RoB 2.0 tool for randomized controlled trial (RCTs) and the Newcastle-Ottawa Scale for observational studies.
resultsPlatelet-rich plasma therapy led to significant improvements in patient-reported outcomes. Pain scores (visual analog scale) showed a pooled standardized mean difference (SMD) of -0.78 (95% CI -1.15 to -0.41; p < 0.0001), whereas Interstitial Cystitis Symptom Index, Interstitial Cystitis Problem Index, and O'Leary-Sant Symptom scores demonstrated SMDs of -0.79, -0.84, and -1.18 respectively (all p < 0.0001). Functional bladder capacity (FBC) and uroflowmetry values improved, with FBC increasing from 267.6 ml to 322.0 ml and Qmax from 10.9 ml/s to 18.4 ml/s in some studies. Improvements were sustained up to 6 months. A low incidence of mild adverse events (dysuria, hematuria, UTIs) was reported. Symptom relief was consistent across short- and long-term follow-up groups, with no statistically significant differences between durations.
conclusionsIntravesical PRP significantly improves pain, urinary symptoms, and bladder function in patients with IC/BPS, while maintaining a low risk of adverse effects. However, larger, well-designed RCTs are needed to confirm long-term efficacy and optimize treatment protocols.
Indexed as
Identifiers
41920327What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.